학술논문
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Document Type
Article
Author
Source
Subject
*MULTIPLE myeloma
*THROMBOEMBOLISM
*LENALIDOMIDE
*RIVAROXABAN
*ASPIRIN
*PULMONARY embolism
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
Summary: Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low‐dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates. [ABSTRACT FROM AUTHOR]